Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 Aug 28;184(3):873–880. doi: 10.1007/s10549-020-05890-1

Table 2.

Final pathology at time of surgical excision in patients with pure ADH-BD diagnosed on core biopsy (n = 236)

Final pathology n (%)

DCIS/invasive carcinoma 108 (45.8)
 DCIS 95 (40.3)
 Invasive carcinoma 13 (5.5)
High-risk lesion 82 (34.7)
 ADH-BD 10 (4.2)
 ADH 33 (14.0)
 ADH and lobular neoplasia 18 (7.6)
 Lobular neoplasia 21 (8.9)
Benign pathology 46 (19.5)

CNB core needle biopsy, ADH-BD atypical ductal hyperplasia bordering on ductal carcinoma in situ, ADH atypical ductal hyperplasia